Loading...
Target Audience: Medical oncologists; radiation oncologists; and oncology surgeons, nurses, and patients
The introduction of HER2-directed therapy significantly improved outcomes for patients with HER2-positive breast cancer. The American Society of Clinical Oncology (ASCO) recently convened an expert panel to update its recommendations, which were last revised in 2014, for patients with disease. The panel conducted a targeted, systematic literature review of 622 publications that appeared during this time period relevant to this patient population. Fundamentally, the recommendations have not changed since the last update 4 years ago.